Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy

Colloids and Surfaces B: Biointerfaces

Volumn 141, Issue , 2016, Pages 74-82

  Eloy, Josimar O ^a,b   Petrilli, Raquel ^a,b   Topan, José Fernando ^a   Antonio, Heriton Marcelo Ribeiro ^a   Barcellos, Juliana Palma Abriata ^a   Chesca, Deise L ^a   Serafini, Luciano Neder ^a   Tiezzi, Daniel G ^a   Lee, Robert J ^b   Marchetti, Juliana Maldonado ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Co loading; Liposomes; Paclitaxel; Rapamycin

Indexed keywords

CELL CULTURE; DRUG INTERACTIONS; ENCAPSULATION; LIPOSOMES; PARTICLE SIZE; THERMOANALYSIS; TUMORS;

BREAST CANCER; BREAST CANCER TREATMENT; CO LOADING; DRUG DELIVERY SYSTEM; ENCAPSULATION EFFICIENCY; NANOMETRIC PARTICLES; PACLITAXEL; RAPAMYCIN;

DISEASES;

LIPOSOME; MACROGOL 2000; PACLITAXEL; RAPAMYCIN; 1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE-N-METHOXY-POLY(ETHYLENE GLYCOL 2000); ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; PHOSPHATIDYLETHANOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; THERMAL ANALYSIS; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; BIOAVAILABILITY; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; PATHOLOGY; SURVIVAL ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; LIPOSOMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; PACLITAXEL; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; SIROLIMUS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84961345883     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2016.01.032     Document Type: Article

References (58)

1. Yin T., Wang L., Yin L., Zhou J., Huo M. Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer. Biomaterials 2015, 61:10-25.
2. Ramadass S.K., Anantharaman N.V., Subramanian S., Sivasubramanian S., Madhan B. Paclitaxel/epigallocatechin gallate coloaded liposome: a synergistic delivery to control the invasiveness of MDA-MB-231 breast cancer cells. Colloids Surf. B: Biointerfaces 2015, 125:65-72.
3. Zhang H., Cohen A.L., Krishnakumar S., Wapnir I.L., Veeriah S., Deng G., Coram M.A., Piskun C.M., Longacre T.A., Herrler M., Frimannsson D.O., Telli M.L., Dirbas F.M., Matin A.C., Dairkee S.H., Larijani B., Glinsky G.V., Bild A.H., Jeffrey S.S. Patient derived xenografts of triple negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res. 2014, 16:1-16.
4. Kouldelka S., Turánek J. Liposomal paclitaxel formulations. J. Controlled Release 2012, 163:322-334.
5. Luo T., Wang J., Yin Y., Hua H., Jing J., Sun X., Li M., Zhang Y., Jiang Y. (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res. 2010, 12:1-10.
6. Sonnichsen D.S., Relling M.V. Clinical pharmacokinetics of paclitaxel. Clin. Pharmacokinet. 1994, 27:256-269.
7. He X., Wang Y., Zhu J., Orlaff M., Eng C. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. Cancer Lett. 2011, 301:168-176.
8. Hasenstein J.R., Shin H.C., Kasmerchak K., Buehler D., Kwon G.S., Kozak K.R. Antitumor activity of triolimus: a novel multidrug-loaded micelle containing paclitaxel, rapamycin, and 17-AAG. Mol. Cancer Ther. 2012, 11:2233-2242.
9. Mondesire W.H., Jian W., Zhang H., Ensor J., Hung M.-C., Mills G.B., Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 2004, 10:7031-7042.
10. VanderWeele D.J., Zhou R., Rudin C.M. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol. Cancer Ther. 2004, 3(12):1605-1613.
11. Blanco E., Sangai T., Wu S., Hsiao A., Ruiz-Esparza G.U., Gonzalez-Delgado C.A., Cara F.E., Granados-Principal S., Evans K.W., Akcakanat A., Wang Y., Do K.A., Meric-Bernstam F., Ferrari M. Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTORpathway. Mol. Ther. 2014, 22:1310-1319.
12. Acevedo-Gadea C., Hatzis C., Chung G., Fishbach N., Lezon-Geyda K., Zelterman D., DiGiovanna M.P., Harris L., Abu-Khalaf M.M. Sirolimus and trastuzumab combination therapy for HER2 positive metastatic breast cancer after progression onprior trastuzumab therapy. Breast Cancer Res. Treat. 2015, 150:157-167.
13. LoRusso P.M. Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment. Oncology 2013, 84:43-56.
14. Vicier C., Dieci M.V., Arnedos M., Delaloge S., Viens P., Andre F. Clinical development of mTOR inhibitors in breast cancer. Breast Cancer Res. 2014, 16:1-9.
15. Malahati K., Kahan B.D. Clinical pharmacokinetics of sirolimus. Clin. Pharmacokinet. 2001, 40:573-585.
16. Yoshizawa Y., Kono Y., Ogawara K.I., Kimura T., Higaki K. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int. J. Pharm. 2011, 412:132-141.
17. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., Baker J.R., Van Echo D.A., Von Hoff D.D., Leyland-Jones B. Hypersensitivity reactions from taxol. J. Clin. Oncol. 2016, 8(1190):1263-1268.
18. Mita M.M., Mita A., Rowinsky E.K. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin. Breast Cancer 2003, 4:126-137.
19. Yatscoff R.W. Pharmacokinetics of rapamycin. Transpl. Proc. 1996, 28:970-973.
20. Eloy J.O., de Souza M.C., Petrilli R., Barcellos J.P.A., Lee R.J., Marchetti J.M. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids Surf. B: Biointerfaces 2014, 123:345-363.
21. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics incancer chemotherapy; mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986, 46:6387-6392.
22. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Delivery Rev. 2013, 65:36-48.
23. Teow H.M., Z, Zhou, M, Najilah S.R., Yusof N.J., Abbott, D'Emanuele A. Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. Int. J. Pharm. 2013, 441:701-711.
24. Emami J., Rezazadeh M., Hasanzadeh F., Sadeghi H., Mostafavi H.A., Minaiyan M., Rostami M., Davies N. Development and in vitro/in vivo evaluation of a novel targeted polymeric micelle for delivery of paclitaxel. Int. J. Biol. Macromol. 2015, 80:29-40.
25. Le Broc-Ryckewaert D., Carpentier R., Lipka E., Daher S., Vaccher C., Betbeder D., Furman C. Development of innovative paclitaxel-loaded small PLGA. nanoparticles: study of their antiproliferative activity and their molecular interactions on prostatic cancer cells. Int. J. Pharm. 2013, 454:712-719.
26. Yang T., Cui F.D., Choi M.K., Cho J.W., Chung S.J., Shim C.K., Kim D.D. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int. J. Pharm. 2007, 338:317-326.
27. Haeri A., Sadeghian S., Rabbani S., Anvari M.S., Boroumand M.A., Dadashzadeh S. Use of remote film loading methodology to entrap sirolimus into liposomes: preparation characterization and in vivo efficacy for treatment of restenosis. Int. J. Pharm. 2011, 414:16-27.
28. I.C.H International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH Harmonised Tripartite Guideline Validation of Analytical Procedures: Text and Methodology Q2(R1) 2005, I.C.H.
29. Chen M.X., Li B.K., Yin D.K., Liang J., Li S.S., Peng D.Y. Layer-by-layer assembly of chitosan stabilized multilayered liposomes for paclitaxel delivery. Carbohydr. Polym. 2014, 111:298-304.
30. de Souza M.C., Marotta-Oliveira S.S., Rocha N.H.S., Eloy J.O., Marchetti J.M. Development of a method to evaluate the release profile of tamoxifen from pegylated hybrid micelles. J. Liquid Chromatogr. Related Technol. 2015, 38:1223-1229.
31. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
32. Meraz I.M., Hearnden C.H., Liu X., Yang M., Williams L., Savage D.J., Gu J., Rhudy J.R., Yokoi K., Lavelle E.C., Serda R.E. Multivalent presentation of MPL by porous silicon microparticles favors T helper 1 polarization enhancing theanti-tumor efficacy of doxorubicin nanoliposomes. PLoS One 2014, 9.
33. Lu J., Huang Y., Zhao W., Chen Y., Li J., Gao X., Venkataramanan R., Li S. Design and characterization of PEG-derivatized vitamin E as a nanomicellar formulation for delivery of paclitaxel. Mol. Pharm. 2013, 10:2880-2890.
34. Crosasso P., Ceruti M., Brusa P., Arpicco S., Dosio F., Cattel L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J. Controlled Release 2000, 63:19-30.
35. Zhang J.A., Anyarambhatla G., Ma L., Ugwu S., Xuan T., Sardone T., Ahmad I. Development and characterization of a novel cremophorw EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur. J. Pharm. Biopharm. 2005, 59:177-187.
36. Yang T., Choi M.K., Cui F.D., Kim J.S., Chung S.J., Shim C.K., Kim D.D. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J. Control Release 2007, 120:169-177.
37. Kirby C., Clarke J., Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem. J. 1980, 186:591-598.
38. Senior J., Gregoriadis G. Stability of small unilamella liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci. 1982, 30:2123-2136.
39. Maruyama K., Yuda T., Okamoto A., Ishikura C., Kojima S., Iwatsuru M. Effect of molecular weight in amphipathic polyethyleneglycol on prolonging the circulation time of large unilamellar liposomes. Chem. Pharm. Bull. 1991, 39:1620-1622.
40. Paini M., Daly S.R., Aliakbarian B., Fathi A., Tehrany E.A., Perego P., Dehghani F., Valtchev P. An efficient liposome based method for antioxidants encapsulation. Colloids Surf B: Biointerfaces 2015, 136:1067-1072.
41. Wagner A., Vorauer-Uhl K. Liposome technology for industrial purposes. J. Drug Delivery 2011, 2011.
42. Eloy J.O., Marchetti J.M. Solid dispersions containing ursolic acid in poloxamer 407 and PEG 6000: a comparative study of fusion and solvent methods. Powder Technol. 2014, 253:98-106.
43. Eloy J.O., Saraiva J., Albuquerque S., Marchetti J.M. Solid dispersion of ursolic acid in gelucire 50/13: a strategy to enhance drug release and trypanocidal activity. AAPS PharmSciTech. 2012, 13:1436-1445.
44. Martins K.F., Messias A.D., Leite F.L., Duek E.A.R. Preparation and characterization of paclitaxel-loaded PLDLA microspheres. Mater. Res. 2014, 17:650-656.
45. Bian H., Zhou S., Liang X., Li Q., Han W. In vitro study of poly(ethylene carbonate) as a drug-eluting stent coating. Prog. Nat. Sci.: Mater. Int. 2012, 22:295-302.
46. Liggins R.T., Hunter W.L., Burt H.M. Solid-state characterization of paclitaxel. J. Pharm. Sci. 1997, 86:1458-1463.
47. Rouf M.A., Vural I., Billensoy E., Hincal A., Erol D.D. Rapamycin-cyclodextrin complexation: improved solubility and dissolution rate. J. Inclusion Phenom. Macrocyclic Chem. 2011, 70:167-175.
48. Rouf M.A., Vural I., Renoir J.M., Rincal A.A. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. J. Liposome Res. 2009, 19:322-331.
49. Ghanbarzadeh S., Arami S., Pourmoazzen Z., Khorrani A. Improvement of the antiproliferative effect of rapamycin on tumorcell lines by poly (monomethylitaconate)-based pH-sensitive, plasmastable liposomes. Colloids Surf. B: Biointerfaces 2014, 115:323-330.
50. Liu Y., Ji M., Wong M.K., Joo K.I., Wang P. Enhanced therapeutic efficacy of irgd-conjugated crosslinked multilayer liposomes for drug delivery. BioMed. Res. Int. 2013, 2013.
51. Shin H.C., Alani A.W.G., Cho H., Bae Y., Kolesar J.M., Kwon G.S. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. Mol. Pharm. 2011, 8:1257-1265.
52. Pulaski B.A., Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr. Protoc. Immunol. 2001.
53. Poondru S., Parchment R.E., Purohit V., LoRusso P., Horwitz J.P., Hazeldine S.T., Polin L., Corbett T., Jasti B.R. Lack of in vitro-in vivo correlation of a novel investigational anticancer agent, SH30. Invest. New Drugs 2002, 20:23-33.
54. Palma G., Conte C.A., Barbieri S., Bimonte, Luciano A., Rea D., Ungaro F., Tirino P., Quaglia F.F., Arra C. Antitumor activity of PEGylated biodegradable nanoparticles for sustained. release of docetaxel in triple-negative breast cancer. Int. J. Pharm. 2014, 473:55-63.
55. Yoshizawa Y., Ogawara K.-I., Kimura T., Higaki K. A novel approach to overcome multidrug resistance: utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors. Eur. J. Pharm. Sci. 2014, 62:274-280.
56. Pawarode A., Minderman H., O'loughilin K.L., Greco W.R., Baer M.R. Rapamycin overcomes multidrug resistance (MDR) mediated by P-glycoprotein (Pgp), multidrug resistance protein-1 (MRP-1), breast cancer resistance protein (BCRP) and lung resistance protein (LRP) and synergizes with substrate drugs in MDR cells. Cancer Res. 2006, 66:1270.
57. Kopecka J., Salzano G., Campia I., Lusa S., Ghigo D., De Rosa G., Riganti C. Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition, nanomedicine: nanotechnology. Biol. Med. 2014, 10:77-87.
58. Mallick S., Choi J.S. Liposomes: versatile and biocompatible nanovesicles for efficient biomolecules delivery. J. Nanosci. Nanotechnol. 2014, 14:755-765.